CAS: 76-77-7 - Neoquassin
Formule :C22H30O6
InChI :InChI=1S/C22H30O6/c1-10-7-14(26-5)20(25)22(4)12(10)8-15-21(3)13(9-16(23)28-15)11(2)18(27-6)17(24)19(21)22/h7,10,12-13,15-16,19,23H,8-9H2,1-6H3
Code InChI :InChIKey=BDQNCUODBJZKIY-UHFFFAOYSA-N
SMILES :O=C1C(OC)=C(C)C2CC(O)OC3CC4C(C=C(OC)C(=O)C4(C)C1C32C)C
- Synonymes :
- 16-Hydroxy-2,12-Dimethoxypicrasa-2,12-Diene-1,11-Dione
- Neoquassine
- Nigakihemiacetal B
- Nsc 139168
- Phenanthro[10,1-bc]pyran, picrasa-2,12-diene-1,11-dione deriv.
- Phenanthro[10,1-bc]pyran-1,11-dione, 3a,4,5,6a,7,7a,8,11a,11b,11c-decahydro-5-hydroxy-2,10-dimethoxy-3,8,11a,11c-tetramethyl-
- Picrasa-2,12-diene-1,11-dione, 16-hydroxy-2,12-dimethoxy-
- Picrasa-2,12-diene-1,11-dione, 16-hydroxy-2,12-dimethoxy- (9CI)
- Simalikahemiacetal A
- Neoquassin
- Voir d'autres synonymes
- Neoquassin
Marque | Informations sur le produit | Degré de pureté | Gamme de prix | Livraison estimée |
---|---|---|---|---|
Picrasa-2,12-diene-1,11-dione,16-hydroxy-2,12-dimethoxy- REF : IN-DA008PDHCAS : 76-77-7 | 98.0% | 252,00 €~611,00 € | mar 07 Jan 25 | |
Neoquassin REF : BP-BP4966CAS : 76-77-7 | 95%~99% | 248,00 €~441,00 € | ven 10 Jan 25 | |
Neoquassin REF : TM-TN1986CAS : 76-77-7 | 98% | À demander | ven 10 Jan 25 | |
Neoquassin REF : 4Z-N-139001CAS : 76-77-7 | - - - | À demander | mar 14 Jan 25 | |
Neoquassin REF : 5G-83573CAS : 76-77-7 | ≥ 98.0 % (HPLC) | 243,00 €~16.456,00 € | jeu 16 Jan 25 | |
Neoquassin REF : 3D-AAA07677CAS : 76-77-7 | Min. 95% | À demander | mar 18 Fév 25 |
Picrasa-2,12-diene-1,11-dione,16-hydroxy-2,12-dimethoxy-
Ref: IN-DA008PDH
5mg | 252,00 € |
Ref: BP-BP4966
5mg | 248,00 € | ||
10mg | 441,00 € |
Neoquassin
Ref: TM-TN1986
5mg | 136,00 € | ||
1mL*10mM (DMSO) | 155,00 € |
Ref: 4Z-N-139001
10mg | À demander | ||
25mg | À demander | ||
50mg | À demander | ||
100mg | À demander |
Neoquassin
Ref: 5G-83573
10mg | 243,00 € | ||
50mg | 988,00 € | ||
250mg | 4.663,00 € | ||
500mg | 8.777,00 € | ||
1000mg | 16.456,00 € |
Neoquassin
Ref: 3D-AAA07677
25mg | À demander | ||
50mg | À demander | ||
100mg | À demander |